Pharmaceutical compositions for the prevention and / or treatment of atopic dermatitis containing an IL-31 antagonist as an active ingredient.

Abstract

In one non-limiting embodiment, a pharmaceutical composition for the prevention and / or treatment of atopic dermatitis containing an IL-31 antagonist as an active ingredient is provided, wherein the aforementioned IL-31 antagonist is administered repeatedly at the same dosage and interval to subjects suffering from atopic dermatitis or at risk of suffering from atopic dermatitis at a dosage of 0.1 mg to 1000 mg / body / 1 day to 12 weeks, preferably 0.1 mg to 1000 mg / body / 2 weeks, 0.1 mg to 1000 mg / body / 4 weeks, or 0.1 mg to 1000 mg / body / 8 weeks.